Last reviewed · How we verify

NCT03321292

L-arginine in Treatment of Intrauterine Growth Restriction

Status unknown NA Last updated 14 August 2018
What this trial tests

NA trial testing L-arginine 1000 mg and Acetylesalicylic acid75mg in Intrauterine Growth Restriction Asymmetrical in 260 participants. Status unknown.

Timeline
15 October 2017
Primary endpoint
1 December 2018
30 December 2018

Quick facts

Lead sponsorAin Shams University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment260
Start date15 October 2017
Primary completion1 December 2018
Estimated completion30 December 2018
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 20 to 40, female only, with Intrauterine Growth Restriction Asymmetrical. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intrauterine growth restriction is an important problem in neonatal care. Intrauterine growth restriction (IUGR) is defined as a fetal weight below the 10th percentile for gestational age. One of the main causes of IUGR is placental insufficiency. Nitric oxide(NO) increases placental blood flow. So,it might be useful to improve IUGR pregnancy outcome .

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy.
    Pels A, Ganzevoort W, Kenny LC, Baker PN, et al · · 2023 · cited 12× · PMID 37428872 · DOI 10.1002/14651858.cd014498

Verify or expand the search:

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03321292.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing